DMD drug developers stake out territory in rare disease market
This article was originally published in Scrip
Executive Summary
Parents of boys with Duchenne muscular dystrophy (DMD) have had little good news during the past few months due to setbacks for Prosensa and Sarepta Therapeutics, but three different biotechnology company presentations at the 32nd Annual JP Morgan Healthcare Conference offered signs of hope for therapies that may keep their sons from losing the ability to walk, eat and breathe on their own.
You may also be interested in...
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.
Finance Watch: Biopharma IPOs Slow But SPACs Back On The Go
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
BMS Makes The Case For A Lasting Hematology Legacy
Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.